A Safe and Potent Anti-Cd19 CAR T Cell Therapy
Zhitao Ying,Xue F. Huang,Xiaoyu Xiang,Yanling Liu,Xi Kang,Yuqin Song,Xiaokai Guo,Hanzhi Liu,Ning Ding,Tingting Zhang,Panpan Duan,Yufu Lin,Wen Zheng,Xiaopei Wang,Ningjing Lin,Meifeng Tu,Yan Xie,Chen Zhang,Weiping Liu,Lijuan Deng,Shunyu Gao,Lingyan Ping,Xuejuan Wang,Nina Zhou,Junqing Zhang,Yulong Wang,Songfeng Lin,Mierzhati Mamuti,Xueyun Yu,Lizhu Fang,Shuai Wang,Haifeng Song,Guan Wang,Lindsey Jones,Jun Zhu,Si-Yi Chen
DOI: https://doi.org/10.1038/s41591-019-0421-7
IF: 82.9
2019-01-01
Nature Medicine
Abstract:Anti-CD19 chimeric antigen receptor (CAR) T cell therapies can cause severe cytokine-release syndrome (CRS) and neurotoxicity, impeding their therapeutic application. Here we generated a new anti-CD19 CAR molecule (CD19-BBz(86)) derived from the CD19-BBz prototype bearing co-stimulatory 4-1BB and CD3ζ domains. We found that CD19-BBz(86) CAR T cells produced lower levels of cytokines, expressed higher levels of antiapoptotic molecules and proliferated more slowly than the prototype CD19-BBz CAR T cells, although they retained potent cytolytic activity. We performed a phase 1 trial of CD19-BBz(86) CAR T cell therapy in patients with B cell lymphoma (ClinicalTrials.gov identifier NCT02842138 ). Complete remission occurred in 6 of 11 patients (54.5%) who each received a dose of 2 × 10 8 –4 × 10 8 CD19-BBz(86) CAR T cells. Notably, no neurological toxicity or CRS (greater than grade 1) occurred in any of the 25 patients treated. No significant elevation in serum cytokine levels after CAR T cell infusion was detected in the patients treated, including in those who achieved complete remission. CD19-BBz(86) CAR T cells persistently proliferated and differentiated into memory cells in vivo. Thus, therapy with the new CD19-BBz(86) CAR T cells produces a potent and durable antilymphoma response without causing neurotoxicity or severe CRS, representing a safe and potent anti-CD19 CAR T cell therapy.